Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical

Retrospective analysis of Claudin 18.2 expression in 64 patients with advanced gastrointestinal peritoneal disease: a potential therapeutic target for high-grade appendiceal mucinous carcinoma

Summary

This retrospective study investigated Claudin 18.2 (CLDN18.2) expression via immunohistochemistry in 64 patients with advanced gastrointestinal peritoneal disease. The aim was to assess CLDN18.2's potential as a therapeutic target beyond upper gastrointestinal cancers. Results revealed significant CLDN18.2 expression in a subset of appendiceal peritoneal metastases, particularly in high-grade appendiceal mucinous carcinomas (22% strong positivity). In contrast, expression was low in colorectal adenocarcinomas. These findings suggest CLDN18.2 could be a promising therapeutic target for patients with appendiceal mucinous carcinomas, potentially offering new options where curative treatments are limited.

Critical appraisal

This retrospective study explores CLDN18.2 expression in peritoneal metastases, identifying a subgroup of high-grade appendiceal mucinous carcinomas (22% strong positivity) as potentially eligible for targeted therapy. CLDN18.2 is already a predictive biomarker for zolbetuximab in upper gastrointestinal cancers, and this research extends its potential application. While retrospective, these data warrant prospective studies, potentially phase II trials, to evaluate the efficacy of zolbetuximab or other CLDN18.2-targeting agents in these patients. Clinical impact could be seen within 3-5 years if these findings are validated, offering new options for a patient population with limited therapeutic choices.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology